Chemical formula: C₂₆H₂₆F₃N₃O₃ Molecular mass: 485.507 g/mol PubChem compound: 24775005
Sonidegib is an orally bioavailable inhibitor of the Hh signalling pathway. It binds to Smoothened (Smo), a G protein-coupled receptor-like molecule that positively regulates the Hh pathway. Aberrant Hh signalling has been linked to the pathogenesis of several types of cancer, including basal cell carcinoma (BCC). Sonidegib binding to Smo will inhibit Hh signalling and consequently block signal transduction.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| L01XJ02 | L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XJ Hedgehog pathway inhibitors | |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| ODOMZO Hard capsule | European Medicines Agency (EU) | MPI, EU: SmPC |
Sonidegib is an active ingredient of these brands:
United States (US)
Australia (AU)
Austria (AT)
Canada (CA)
Croatia (HR)
Estonia (EE)
Finland (FI)
France (FR)
Ireland (IE)
Israel (IL)
Italy (IT)
Lithuania (LT)
New Zealand (NZ)
Poland (PL)
Spain (ES)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
